Chronic infection with hepatitis C virus is the major cause of liver cirrhosis and carcinoma and is responsible for approximately half of the indications for liver transplantation worldwide. Liver transplantation represents an effective treatment option but graft re-infection is virtually inevitable in those patients with detectable serum hepatitis C virus RNA at the time of transplant. In a very interesting review, Toniutto and colleagues (2008) consider the effectiveness of antiviral treatment of hepatitis C-positive patients awaiting liver transplant. Interferon in combination with ribavirin represent the mainstay treatments and in addition to improving graft survival; antiviral treatment may remove the need for a liver transplant thereby saving scarce donated organs. Although this approach appears effective, the authors recommend caution as results obtained to date are from small and uncontrolled clinical studies of less than 300 patients with a relative short period of follow-up. They conclude by stating that in those transplant centres where the time of the operation can be predicted with some degree of accuracy, limited antiviral regimens including novel drugs might prove to be effective in hepatitis C virus-infected patients.
Neff and colleagues (2008) review treatment options for mucous membrane pemphigoid (MMP). This is an autoimmune blistering disorder of mucous membranes characterized by subepithelial bullae involving the oral cavity, conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. Skin involvement is observed in approximately one-quarter of patients and is usually limited to the head, neck and upper torso. MMP presents with a spectrum of symptoms; the authors describe diagnostic criteria and clinical features and how these inform the various treatment options for this condition. Three monoclonal tumour necrosis factor-α (TNF-α) inhibitors are currently available: etanercept, infliximab, and adalimumab. All have efficacy in the treatment of rheumatoid arthritis and with a more variable response in other granulomatous diseases such as sarcoidosis, Crohn’s disease or Wegener’s granulomatosis. It is of interest therefore that anti-TNF-α agents also appear effective in MMP that is refractive to treatment with more established therapies. The authors conclude by pointing out that as MMP is a relatively rare disorder there is a lack of well-conducted, large, randomized controlled trials comparing the efficacy of various therapeutic agents and that a multidisciplinary approach is recommended for identifying the appropriate therapy for each individual patient.